272

Mabion SA

Healthcare · EUR · F

272

Price

€1.691

+2.42%

Cap

€27.35M

Earnings

30d Trend

-8.8%

272
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

50% annualised over 90 days

BRAIN47 SIGNAL

0
WEAK
Risk Level65
Quality25
Momentum36
Technical44
Fundamentals35

Raw weighted: 34×Macro 0.99 (1%)=34

RISK

65/100
90d Volatility
49.6%High
ATR %
3.0%Normal
Max Drawdown (1Y)
-31.6%Volatile

QUALITY

25/100
ROE (avg)
-78.1%*Negative
Piotroski F-Score
2/9Weak
Margin Stability
CV 24.5%Volatile
Accruals
-19.0%Cash earnings

MOMENTUM

36/100
12-1M Momentum
-19.6%Strong downtrend
6-1M Momentum
+0.0%Flat
1M Return
-2.5%Stable

TECHNICAL

44/100
RSI (14)
44.5Neutral
Price vs SMA200
-11.0%Bearish trend
MACD
0.00Bearish momentum
Bollinger Band
41%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.189Noisy/choppy

FUNDAMENTALS

35/100
P/S
7.2Fair

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months44
3-12 months33
1-5+ years29

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate Mabion SA at 34/100 — a WEAK reading on the Brain47 Signal. The strongest factor is technical at 44/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-2.5%

3 MONTHS

-10.9%

12 MONTHS

-22.2%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Technical (44) and Momentum (36) are the primary strengths. I note that quality is the weakest area at 25/100 — this warrants monitoring. Historical volatility is elevated at 50%. I classify this as a speculative position — elevated volatility at 50% and smaller market cap define the opportunity.

speculativeScore: 34/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.